Furthermore, ROC curves showed that serum YKL-40 had a good value for predicting 1-year MACE risk (AUC, 0.729; best cut-off value, 109.0 ng/ml; sensitivity, 0.800; specificity, 0.672) (Figure 6A); meanwhile, serum YKL-40 disclosed a general capability for estimating 2-year (AUC, 0.671; best cut-off value, 104.6 ng/ml; sensitivity, 0.750; specificity, 0.578) (Figure 6B) and 3-year (AUC, 0.643; best cut-off value, 104.6 ng/ml; sensitivity, 0.732; specificity, 0.569) (Figure 6C) MACE risk in CHD patients. This evidence concerns the gene CHI3L1 and coronary artery disorder.